Edition:
United Kingdom

Cellectis SA (ALCLS.PA)

ALCLS.PA on Paris Stock Exchange

24.04EUR
18 Sep 2018
Change (% chg)

-- (--)
Prev Close
€24.04
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
52,284
52-wk High
€30.00
52-wk Low
€19.24

Select another date:

Thu, Aug 2 2018

BRIEF-Cellectis Operating Loss Widens To 21.7 Million US Dollars

* SAID ON WEDNESDAY ITS Q2 REVENUES WERE $5.0 MLN VS $6.5 MLN YEAR AGO

BRIEF-Cellectis Publishes Methods to Improve Clinical Use of Chimeric Antigen Receptor T-Cell Therapy

* ANNOUNCED ON TUESDAY NOVEL METHODS TO IMPROVE THE CLINICAL USE OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY

BRIEF-Cellectis Announces Approval Of Amendment To Protocol For UCART123 Phase 1 Clinical Trial

* ANNOUNCED ON TUESDAY APPROVAL OF AMENDMENT TO PROTOCOL FOR PHASE 1 CLINICAL TRIAL OF UCART123 PRODUCT CANDIDATE IN ACUTE MYELOID LEUKEMIA (AML) PATIENTS

BRIEF-Cellectis Submits Investigational New Drug Application To FDA For UCART22

* SAID ON WEDNESDAY IT HAS SUBMITTED INVESTIGATIONAL NEW DRUG (IND) APPLICATION TO THE US FDA REQUESTING APPROVAL TO INITIATE A PHASE 1 CLINICAL TRIAL FOR UCART22

BRIEF-Cellectis Partners With Harvard’S Wyss Institute For Research On Human Genome

* SAID ON TUESDAY THAT HARVARD’S WYSS INSTITUTE PARTNERS WITH CELLECTIS TO RECODE HUMAN GENOME

BRIEF-Cellectis Announces Launch Of 175 Million Dollar Underwritten Public Offering Of Its American Depositary Shares

* ANNOUNCED ON WEDNESDAY LAUNCH OF FOLLOW-ON UNDERWRITTEN PUBLIC OFFERING OF $175 MLN OF ITS AMERICAN DEPOSITARY SHARES (ADS)

Select another date: